Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivo

Table 1 Inhibitory effect of NM-3 on gastric cancer growth (mean ± SD)

Groups	n	MTV (mm3)	Body weight (g)	Tumor weight (mg)	TGI (%)
Normal saline	10	81.24 ± 12.63	25.8 ± 1.04	1754.0 ± 144.2
NM-3 (10 mg/kg)	10	79.68 ± 13.72	24.4 ± 0.76	1351.0 ± 116.9	23.0a
NM-3 (20 mg/kg)	10	81.08 ± 12.90	23.1 ± 0.82	1041.1 ± 143.5	40.6a
NM-3 (40 mg/kg)	8	81.36 ± 11.20	22.9 ± 1.06	765.5 ± 140.1	56.2ac
NM-3 (10 mg/kg) + carplatin	10	80.29 ± 14.26	24.2 ± 0.88	1002.0 ± 101.4	42.7ac
NM-3 (20 mg/kg) + carplatin	10	82.30 ± 14.53	24.4 ± 0.78	919.0 ± 149.8	47.6ac
NM-3 (40 mg/kg) + carplatin	8	81.97 ± 12.77	22.5 ± 1.13	645.7 ± 135.1	63.2ac
Carplatin	10	80.01 ± 13.67	23.0 ± 1.03	1655.0 ± 157.4	5.6

^aP < 0.05 vs normal saline control group and carboplatin group,

^cP < 0.05 vs NM-3 (10 mg/kg) group.

Table 2 Effect of NM-3 on cell apoptosis of gastric cancer (mean ± SD, %)

Groups	n	AI (TUNEL )	AI (FAScan)
Normal saline	10	2.12 ± 2.19	1.59 ± 0.24
NM-3 (10 mg/kg)	10	6.02 ± 1.63a	3.84 ± 0.68a
NM-3 (20 mg/kg)	10	10.43 ± 3.15ac	8.21 ± 1.01ac
NM-3 (40 mg/kg)	8	22.06 ± 5.68ac	18.26 ± 4.46ac
NM-3 (10 mg/kg) + carplatin	10	8.66 ± 2.35ac	6.96 ± 0.65ac
NM-3 (20 mg/kg) + carplatin	10	12.63 ± 3.75ac	10.65 ± 1.43ac
NM-3 (40 mg/kg) + carplatin	8	24.63 ± 3.67ac	21.66 ± 2.96ac
Carplatin	10	2.47 ± 0.31	1.85 ± 0.34

^aP < 0.05 vs normal saline control group and carboplatin group,

^cP < 0.05 vs NM-3 (10 mg/kg) group.

Table 3 Effect of NM-3 on MVD (mean ± SD)

Groups	n	MVD
Normal saline	10	7.30 ± 0.53
NM-3 (10 mg/kg)	10	5.10 ± 0.40a
NM-3 (20 mg/kg)	10	4.72 ± 0.51a
NM-3 (40 mg/kg)	8	2.02 ± 0.50ac
NM-3 (10 mg/kg) + carplatin	10	4.96 ± 0.37a
NM-3 (20 mg/kg) + carplatin	10	4.80 ± 0.39a
NM-3 (40 mg/kg) + carplatin	8	1.78 ± 0.42ac
Carplatin	10	6.98 ± 0.45

^aP < 0.05 vs normal saline control group and carboplatin group,

^cP < 0.05 vs NM-3 (10 mg/kg) group.